國立虎尾科技大學 |

Minimal Residual Disease Testing = Current Innovations and Future Directions /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Minimal Residual Disease Testing/ edited by Todd E. Druley.
其他題名:	Current Innovations and Future Directions /
其他作者:	Druley, Todd E.
面頁冊數:	VIII, 197 p. 28 illus., 27 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Hematology. -
電子資源:	https://doi.org/10.1007/978-3-319-94827-0
ISBN:	9783319948270

Minimal Residual Disease Testing = Current Innovations and Future Directions /
Minimal Residual Disease TestingCurrent Innovations and Future Directions /[electronic resource] :edited by Todd E. Druley. - 1st ed. 2019. - VIII, 197 p. 28 illus., 27 illus. in color.online resource.

Introduction -- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma -- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies -- Monitoring AML Response Using “Difference From Normal” Flow Cytometry -- ML-DS: A Unique Condition for Measurable Residual Disease Detection -- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.

This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.

ISBN: 9783319948270

Standard No.: 10.1007/978-3-319-94827-0doiSubjects--Topical Terms:

645254
Hematology.

LC Class. No.: RB45

Dewey Class. No.: 616.15

Minimal Residual Disease Testing = Current Innovations and Future Directions /
LDR:02500nam a22003855i 4500 001 1014089
003 DE-He213
005 20200703094618.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783319948270 $9 978-3-319-94827-0
024 7 $a 10.1007/978-3-319-94827-0 $2 doi
035 $a 978-3-319-94827-0
050 4 $a RB45
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
072 7 $a MJF $2 thema
082 0 4 $a 616.15 $2 23
245 1 0 $a Minimal Residual Disease Testing $h [electronic resource] : $b Current Innovations and Future Directions / $c edited by Todd E. Druley.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a VIII, 197 p. 28 illus., 27 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Introduction -- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma -- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies -- Monitoring AML Response Using “Difference From Normal” Flow Cytometry -- ML-DS: A Unique Condition for Measurable Residual Disease Detection -- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.
520 $a This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.
650 0 $a Hematology. $3 645254
650 0 $a Oncology . $3 1253469
650 0 $a Pathology. $3 668553
650 2 4 $a Oncology. $3 593951
700 1 $a Druley, Todd E. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1308335
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319948263
776 0 8 $i Printed edition: $z 9783319948287
856 4 0 $u https://doi.org/10.1007/978-3-319-94827-0
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)